Project Grant R33CA309730
Award Date 8/13/26
Completion Date 7/31/29
Dollars Obligated $405K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Cancer Institute awarded the University of Washington $686,271 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support proteomics-driven analysis and robotics-enabled drug testing of microdissected tumors and their microenvironment. The funded work develops high-throughput approaches to rapidly dissect thousands of regularly-sized microdissected tumor tissues (MDTs) from single biopsies. Tumor tissue is mechanically cut into approximately...
- The National Cancer Institute awarded the Institute For Systems Biology $555,592 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop AI-driven infrastructure for integrating and analyzing cancer datasets and identifying cancer risk factors. The recipient will construct a multi-modal, harmonized resource for the tumor microenvironment featuring an AI-powered spatial search tool. Using spatial datasets from the Human Tumor Atlas Network (HTAN), the...
- The National Cancer Institute awarded the University of Washington $641,632 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct functional and mechanistic interrogation of kinase complexes and their ligandability. The recipient will use the KICCA approach to study kinase-protein interactions in native cells and tissues across ten cell signaling pathways in 25 cancer cell lines and clinical samples of primary liver cancer. Work includes applying chemical labeling...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $207,802 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop multiplexed multiscale imaging technologies for studying cellular immunotherapies. The recipient will develop new fluorescent probes to simultaneously visualize many proteins at once in immune cells, tumor cells, and at the immune synapse, with spatial resolution ranging from one micron to tens of...
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded the University of Washington $142,780 on January 23, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training in careers in basic, clinical, and prevention research relevant to the National Cancer Program. The award funds research addressing antigen-low tumor escape in non-small cell lung cancer through chimeric T cell receptor (ChTCR) therapy. The project develops engineered ChTCRs that fuse a CAR single-chain variable...
- The National Cancer Institute awarded Washington University $667,491 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a multi-center investigation integrating positron emission tomography imaging and circulating tumor DNA analysis to predict response to PARP inhibitor therapy in metastatic castration-resistant prostate cancer patients. The recipient will lead a three-site imaging trial at Washington University School of Medicine, MD...
- The National Cancer Institute (NCI) awarded $526,939 to Wake Forest University Health Sciences on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for Research Project Grant R01CA304427. The award funds development of multimodal deep learning models that integrate radiological, pathological, and clinical data to predict immunotherapy response and survival outcomes in gastric cancer patients. The project addresses the limited efficacy of immune checkpoint...
- The National Cancer Institute awarded the University of Washington $149,190 on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398) to fund research elucidating the role of type 2 conventional dendritic cells in shaping anti-tumor immunity. The recipient will conduct ex vivo co-culture studies and immunological characterization to test the hypothesis that intratumoral type 2 conventional dendritic cells limit anti-tumor immunity by promoting CD8 T cell exhaustion. The work...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $394,695 to The Ohio State University on June 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate computational approaches for detecting and characterizing infiltrating immune cells in breast cancer. The recipient will develop computational methods to enumerate and phenotype tumor-infiltrating lymphocytes (TILs) and...